Email this article to a friend
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain
-
* Corresponding author: John Thipphawong JThippha@its.jnj.com
BMC Palliative Care 2009, 8:14 doi:10.1186/1472-684X-8-14